Get started
Author

Irene L. M. Reijers

Observed names: I. L. M. Reijers, I. Reijers, I.L.M. Reijers, Irene L M Reijers, Irene L. Reijers, Irene L.M. Reijers, Irene Reijers, Reijers I
Observed institutions: Utrecht University, Leiden University Medical Center, Erasmus MC, The Netherlands Cancer Institute, University Medical Center Utrecht, St. Antonius Ziekenhuis, Antonius Ziekenhuis, Vrije Universiteit Amsterdam
ORCID: 0000-0002-7103-3219
Observed ORCID: 0000-0002-7103-3219
OpenAlex ID: A5022668182
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
2024 · Christian U. Blank, Minke W. Lucas, et al. · New England Journal of Medicine · 552
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
2022 · Irene L. M. Reijers, Alexander M. Menzies, et al. · Nature Medicine · 380
PDF
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
2021 · E. A. Rozeman, E. P. Hoefsmit, et al. · Nature Medicine · 338
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
2022 · Rebecca C. Simpson, Erin R. Shanahan, et al. · Nature Medicine · 254
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
2021 · Ines Pires da Silva, Tasnia Ahmed, et al. · The Lancet Oncology · 222
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
2021 · C.N. Owen, X. Bai, et al. · Annals of Oncology · 172
PDF
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
2019 · Christian Menzer, Alexander M. Menzies, et al. · Journal of Clinical Oncology · 134
PDF
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
2023 · Irene L.M. Reijers, Disha Rao, et al. · The Journal of Experimental Medicine · 82
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
2022 · F. Dimitriou, K. Namikawa, et al. · Annals of Oncology · 70
PDF
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
2020 · Christian U. Blank, Irene L.M. Reijers, et al. · Journal of Clinical Oncology · 62
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
2023 · Itske Fraterman, Irene L. M. Reijers, et al. · Nature Medicine · 58
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
2022 · Irene L. M. Reijers, Robert V. Rawson, et al. · JAMA Surgery · 56
PDF
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
2022 · Paulien Kaptein, Celia Jacoberger-Foissac, et al. · Science Translational Medicine · 52
PDF
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
2024 · Irene L.M. Reijers, Alexander M. Menzies, et al. · European Journal of Cancer · 34
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
2021 · Judith M. Versluis, Irene L.M. Reijers, et al. · European Journal of Cancer · 31
PDF
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
2020 · Ines Pires Da Silva, Tasnia Ahmed, et al. · Journal of Clinical Oncology · 31
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
2023 · Lotte L. Hoeijmakers, Irene L.M. Reijers, et al. · Cancer Discovery · 23
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells
2023 · Esmée P. Hoefsmit, Paula T. van Royen, et al. · Cancer Immunology Research · 22
Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.
2020 · Elisa A. Rozeman, Irene L.M. Reijers, et al. · Journal of Clinical Oncology · 20
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
2019 · Irene Reijers, Elisa A. Rozeman, et al. · Journal of Clinical Oncology · 19
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
2022 · Christian U. Blank, Irene L.M. Reijers, et al. · Journal of Clinical Oncology · 17
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
2022 · Tim B Fessenden, Lauren E Stopfer, et al. · Journal for ImmunoTherapy of Cancer · 16
PDF
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma
2019 · Irene L. M. Reijers, Elisa A. Rozeman, et al. · Pigment Cell & Melanoma Research · 15
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence
2023 · Esmee P. Hoefsmit, Franziska Völlmy, et al. · Cancer Research Communications · 14
PDF
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
2022 · Irene L.M. Reijers, Petros Dimitriadis, et al. · Journal of Clinical Oncology · 12
Works count: 143
Citation count: 2,789
H-index: 19
I10-index: 29
Year
Topic
Type